TSE:MFC

Manulife Financial (MFC.TO)

54.16
+0.66 (1.23%)
as of Jun 5, 2026, 3:33:54 pm Market Open.
1636 watching
0
Investor Insights
star iconJun 5, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) is viewed positively by several analysts, who note its solid growth in Asia and the wealth management sector. The company is seen as a stable and reliable option, with a decent dividend yield that appeals to income-focused investors. Analysts acknowledge that while MFC has experienced some recent challenges, especially in its U.S. operations and corrections after strong performances, it maintains a healthy growth outlook. Concerns about the overall market and macroeconomic factors have led to suggestions of caution, but many believe MFC's valuation is still attractive relative to its peers, particularly the banks. In the long term, it remains a compelling investment opportunity with the potential for growth, other factors such as credit risk being minimal.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
SLF
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly As a quality Canadian company with growing sales volumes, favourable interest rates, and disciplined expense management, we reiterate MFC as a TOP PICK. A favorable product mix, higher margins in annuities and international business are expected to drive future value. It pays a great dividend, backed by a payout ratio under 35% of cash flow. We continue to recommend a stop at $21, looking to achieve $30.50 — upside potential over 23%. Yield 5.2% (Analysts’ price target is $30.31)
TOP PICK
Value name. One of the world's largest lifecos. Asia represents 50% revenue, middle class is growing. Aging global population needs wealth management services. Rising interest rates. Just under 1x price to book, significant discount to peers. Dividend should grow moderately, plus nice capital appreciation. Yield is 5.22%. (Analysts’ price target is $31.70)
PAST TOP PICK
(A Top Pick Jan 11/21, Up 20%) Likes it still, especially with rising interest rates. Lifecos will earn more on their spreads. Still on the cheap side.
BUY
MFC vs. SLF MFC is cheaper, better yield. Rising rates are good for insurance companies broadly, and MFC in particular. Long-term chart shows it has traded higher under normal interest rates conditions. Mild preference for MFC.
BUY
More value right now in lifecos than in banking. GWO is his favourite for the management and capital allocation. But MFC and SLF are both good. MFC is repositioning itself, releasing excess capital. Fundamentally undervalued. Trades at 8x normalized earnings. You could buy and hold for the long term.
WEAK BUY
Caller owns 7,000 shares You should diversify. MFC trades at a discount to the group because it has issues, but management is dealing with that. She expects MFC to catch up, but she is reassessing MFC. She hears how the younger people are leaving Hong Kong, which could dampen MFC's growth in that region.
TRADE
Has had a good run and beat on the 4th quarter. Asia component is good and it is cheap at 6.84 times with 11% growth rate. Concerns relate to long term care component along with new accounting standards. Not buying long. Recommends keeping cash for more opportunities.
BUY
Not sure why so cheap. Trades at a deep discount at only 7X core P/E and earnings are growing. Great dividend yield and is a value oriented play.
BUY
Manulife vs. SunLife He prefers Manulife, though there are concerns about their Asian exposure. But they are selling at slightly over book and SLF higher. MFC also pays a higher yield of over 1%, and the valuation is better with MFC. He owns both and both will benefit from rising interest rates. MFC has been minimizing risk by getting out of their non-core holdings and to concentrate on their profitable businesses, but this demands patience. They are making solid progress as the new CEO focuses on shareholder value.
WEAK BUY
Why trading at a discount to GWO and SLF? Historically, MFC has stumbled, like CIBC in banking. That's why. But all insurers will benefit from higher interest rates, no doubt. So, MFC is not a bad buy at the moment. Among financials, he prefers banks; insurers have to ensure that their assets match their liabilities, so they are more conservative.
BUY ON WEAKNESS
Allan Tong’s Discover Picks As a trade or a medium-term hold, Manulife benefits from rising interest rates and pays a generous 5.22% dividend. It trades at only a 7.27x PE. In the past seven years, MFC tends to plateau slightly above $27 and fails to rise to $28. With the street expecting four rate hikes in 2022, MFC has another shot at cracking at $28. Since Dec. 1, 2021, Manulife has climbed $2 on the tailwind of rising rate talk. Read 3 Oversold Stocks to Buy Right Now for our full analysis.
BUY
Target price is $30. Perpetual underperformer, but it sets up really nicely. Trading at 6.3x 2023, with growth rate over 10%, dividend growth. Almost a no-brainer at this valuation. Good choice for spare cash.
TOP PICK
Steepening yield curve. Wealth management continues to be in more demand. Asia represents 38% of its overall revenue, greater than any of its NA peers, and will benefit long-term from growing middle class. Discount to peer group at 1x price to book. Yield is 4.32%, expected to grow around 10% a year. (Analysts’ price target is $30.44)
DON'T BUY
Company is a tough investment to make. Struggling to recover from mistakes made 10 years ago. Trying to earn return in negative interest rate environment for policy holders + shareholders is difficult.
DON'T BUY
MFC vs. SLF SLF is head and shoulders above MFC. SLF's model price is $78.85 (11% upside), nice yield of 3.2%, seems to be functioning. MFC, on the other hand, has been the same price for the last 15 years.
Showing 196 to 210 of 2,279 entries